Table III.
List of publications concerning esophageal cancer outcomes in the elderly and the most important data about the outcomes
| Authors | Pre-treatment comorbidity assessment score | Mortality, n (%) | All complications/toxicity, n (%) | Overall survival rates (%) | Median overall survival [months] | Recurrent disease, n (%) | |||
|---|---|---|---|---|---|---|---|---|---|
| 1 year | 2 years | 3 years | 5 years | ||||||
| Cummings et al. (OE group) | Charlson/Deyo comorbidity index | 36 (4)2 | 265 (30) | nd | 71 (AC) 60 (SCC) |
nd | nd | nd | 139 (16) |
| Liu, Huang et al.
(≥ 70 y group) |
nd | 3 (7.7)5 | 18 (46.1) | nd | 33.3 | 0 | nd | 15.8 | nd |
| Li et al. (OE group) | nd | 5 (8.6)5 | 35 (60.3) | nd | nd | nd | nd | 22 ±3.4 | nd |
| Aydin et al. | nd | 3 (8.1)1 | 16 (43.2) | 70.3 | nd | 31 | 21.4 | 28.7 | 6 (16.2) |
| Pultrum et al. (≥ 70 y group) | ASA | 7 (11)3 | 44 (69) | 70 | nd | nd | 33 | 26 (range: 0–199) | 27 (42) |
| Liu Chen et al. (≥ 70 y group) | ECOG | 3 (10.3)4 | 15 (51.7) | nd | 20 | 3 | 0 | 12.1 (95% CI: 8.6–15.6) | nd |
| Kosugi et al. (OE group) | ASA | 2 (5)1 | 26 (65.0) | 77.5 | nd | 37.3 | 24.0 | 108.2 (range: 32.5–138.9) | nd |
| Abrams et al. (OE group) | Charlson/Klabunde comorbidity index | 24 (7.7)1 | nd | nd | nd | 53.1 | 44.9 | nd | nd |
| Internullo et al. | ASA | 8 (7.4)5 | 56 (51.9) | nd | nd | nd | 35.7 | 28.5 (range: 0.1–149.5) | (33.3) |
| Ruol et al. (≥ 70 y group) | ASA | 3 (1.9)1 3 (1.9)4 |
78 (49.1) | nd | nd | nd | 35.4 | 17.9 (range: 9.2–44.4) | nd |
| Ma et al. (≥ 70 y group) | nd | 2 (3.3)4 | nd | nd | nd | nd | nd | nd | nd |
| Mirza et al. (≥ 70 y group) | ASA | nd | nd | nd | nd | nd | nd | 10.8 (range: < 1 month to 8.3 years) | 21 (45.65) |
| Li et al. (MIE group) | nd | 2 (3.4)5 | 22 (37.9) | nd | nd | nd | nd | 39 ±8.9 | nd |
| Cummings et al. (ET group) | Charlson/Deyo comorbidity index | nd | 30 (12) | nd | 84 (AC) 76 (SCC) |
nd | nd | nd | 32 (13) |
| Kikuchi et al. (≥ 75 y group) | ASA | 0 (0)5 | 13 (27) | nd | nd | nd | nd | nd | nd |
| Wakui et al. | nd | 4 (18.2)5 | 14 (70) | 44.3 ±10.8 | 34.5 ±10.4 | 15.9 ±10.8 | nd | 23.8 (range: 8.3–53.6) | 11 (55) |
| Kosugi et al. (CRT group) | ASA | 5 (21)6 | nd | 60.9 | nd | 17.4 | 11.6 | 72.5m (range: 12.4–95.3) | 1 (4.1) |
| Abrams et al. (CRT group) | Charlson/Klabunde comorbidity index | nd | nd | nd | nd | 23.9 | 13.9 | nd | nd |
| Tougeron, Di Fiore et al. | Charlson score | 2 (2.2)5 | 62 (56.9) | 56.9 | 19.27 | 6.4 | 15.2 ±2.8 | 31 (28.4) | |
| Anderson et al. | Charlson score | 0 (0)5 | 9 (36) | 80 | 64 | nd | nd | 35 (3–66) | nd |
| Tougeron et al. (curative treatment) | Charlson score | nd | nd | nd | nd | nd | nd | 17.8 ±1.5* 5.5 ±2.0** |
35 (23.17) |
| Tougeron et al. (palliative treatment group) | Charlson score | nd | nd | nd | nd | nd | nd | 6.7 ±2.1 | 7 (23.33) |
| Tougeron et al. (BSC group) | Charlson score | nd | nd | nd | nd | nd | nd | 5.5 ±2.0* 1.8 ±0.4** |
18 (17.82) |
| Tapias et al. (70–79 y group) | nd | 4 (3.2)1 7 (6.1)3 |
77 (62.1) | nd | nd | nd | 41.7 | nd | nd |
| Tapias et al. (≥ 80 y group) | nd | 1 (6.3)1 2 (14.3)3 |
14 (87.5) | nd | nd | nd | 49.2 | nd | nd |
| Steyerberg et al. | Charlson score | nd | nd | 42 | 24 | nd | 11 | 9.63 (95% CI: 9.2–10) | nd |
1
30-day mortality
2
60-day mortality
3
90-day mortality
4
in-hospital mortality
5
no data
6
treatment-related mortality
*
patients without visceral metastasis/metastases
**
patients with visceral metastasis/metastases, nd – no data.